GeoVax Labs, Inc. (GOVX)
| Market Cap | 24.70M |
| Revenue (ttm) | 472,160 |
| Net Income (ttm) | -6.16M |
| Shares Out | 6.38M |
| EPS (ttm) | -1.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 108,725 |
| Open | 3.80 |
| Previous Close | 3.82 |
| Day's Range | 3.75 - 3.95 |
| 52-Week Range | 3.01 - 8.71 |
| Beta | 1.88 |
| Analysts | Buy |
| Price Target | 10.00 (+158.4%) |
| Earnings Date | Nov 11, 2021 |
About GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for GeoVax Labs stock is "Buy" and the 12-month stock price forecast is 10.00.
News
GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress
Nonhuman Primate Testing of Sudan and Marburg Vaccine Candidates Demonstrates Efficacious Immune Response
GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress
GEO-CM02 Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants such as Omicron
GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress
GEO-CM02 Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants
GeoVax Shares Surge After Cancer Vaccine Patent In US
GeoVax Labs Inc (NASDAQ: GOVX) has received a U.S. patent covering its vector platform for expressing tumor-associated antigens in virus-like particles (VLPs). The platform comes from a Modified Vaccini...
GeoVax Labs, Inc. (NASDAQ: GOVX) Receives Notice of Allowance For Cancer Vaccine Patent
GeoVax Labs, Inc. (NASDAQ: GOVX), a biotechnology company developing human immunotherapies and vaccines…
GeoVax Receives Notice of Allowance for Cancer Vaccine Patent
GeoVax Intellectual Property Portfolio Includes More than 70 Granted/Pending Patent Applications
GeoVax Announces Upcoming Presentations at Scientific Conferences
ATLANTA, GA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announ...
GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update
Progress in Clinical Development of COVID-19 and Immuno-Oncology Programs
GeoVax Labs In-Licenses Development Rights To Multi-Antigenic COVID-19 Vaccine Candidate
GeoVax Labs Inc (NASDAQ: GOVX) entered into an exclusive license agreement with City of Hope, a cancer research and treatment organization, for COH04S1, a synthetic, attenuated modified vaccinia Ankara ...
GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope's COVID-1...
Phase 2 Vaccine Designed to Enhance Response for Immunocompromised Patients
GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update
Conference call to be held Thursday, November 11, at 4:30 p.m. Eastern Time
GeoVax Receives Notice of Allowance for Ebola Vaccine Patent
Single-dose of GEO-EM01 Provided 100% Protection in Lethal Challenge Evaluation
GeoVax Stock Is Trading Higher On Gedeptin In-Licensing Pact For Solid Tumors
GeoVax Labs Inc (NASDAQ: GOVX) entered into a license agreement with PNP Therapeutics Inc to develop and commercialize Gedeptin for solid tumors. The transaction's detailed financial terms were not di...
GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program
License of Gedeptin® Adds Orphan Drug Clinical Program for Treatment of Advanced Head and Neck Cancers
GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
Atlanta, GA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc . (Nasdaq: GOVX), a biotechnology company developing human vaccines and cancer immunotherapies, announces today tha...
GOVX Stock: Why GeoVax Shares Are Skyrocketing Today
Geovax Labs (GOVX) stock is soaring higher on Friday after the company presented COVID-19 vaccine data at a recent conference. The post GOVX Stock: Why GeoVax Shares Are Skyrocketing Today appeared firs...
Why Geovax Labs Shares Are Soaring Today
Geovax Labs Inc (NASDAQ: GOVX) is trading significantly higher Friday after the company announced it presented data from ongoing studies of its preventive vaccine against COVID-19 at the European Societ...
GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly
ATLANTA, GA, Aug. 19, 2021 (GLOBE NEWSWIRE) -- GeoVax Vaccine Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants
GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021
ATLANTA, GA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cance...
GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update
Continued Progress on COVID-19 and Immuno-Oncology Programs
GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update
Conference call to be held Wednesday, August 11, at 4:30 p.m. Eastern Time
GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting
GeoVax Vaccine Achieves 100% Protection in a Single-Dose
GeoVax Announces Issuance of Hepatitis B Vaccine Patent
Vaccine Would Address Therapeutic Medical Need of Over 250 Million Worldwide
GeoVax to Participate in the Alliance Global Partners' Virtual Healthcare Symposium
Atlanta, GA, June 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc . (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases a...